OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
Launched by HOFFMANN-LA ROCHE · Dec 18, 2007
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, \>=18 years of age;
- • locally advanced or metastatic colorectal cancer;
- • no previous treatment with chemotherapy for metastatic disease;
- • at least one measurable lesion.
- Exclusion Criteria:
- • radiotherapy to any site within 4 weeks before study;
- • untreated brain metastases or primary brain tumors;
- • clinically significant cardiovascular disease;
- • chronic daily treatment with high dose aspirin (\>325 mg/day);
- • other co-existing malignancies or malignancies diagnosed within last 5 years.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Napoli, , Italy
Pavia, , Italy
Reggio Emilia, , Italy
Padova, , Italy
Palermo, , Italy
Reggio Calabria, , Italy
Brescia, , Italy
Firenze, , Italy
Catanzaro, , Italy
Roma, , Italy
San Giovanni Rotondo, , Italy
Legnago, , Italy
Cagliari, , Italy
Caserta, , Italy
Fano, , Italy
Frattaminore, , Italy
Lecce, , Italy
Rionero In Vulture, , Italy
Salerno, , Italy
Taormina, , Italy
Torino, , Italy
Grosseto, , Italy
Firenze, , Italy
Roma, , Italy
Cefalu, , Italy
Ivrea, , Italy
Latisana, , Italy
Legnano, , Italy
Macerata, , Italy
Negrar, , Italy
Orbassano, , Italy
Sondrio, , Italy
Verbania, , Italy
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials